Page 63 - Approval Program News Today

17.12.2021 - New dispersible tablet dosage form also approved Oxbryta is the first medicine that addresses the root cause of red blood cell sickling SOUTH SAN FRANCISCO, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) - Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ...

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia

/PRNewswire/ -- Novartis today announced new 48-week data from the Phase III ASCEMBL trial of Scemblix® (asciminib) demonstrating that the results observed in...

Updated 48-week data from Phase III ASCEMBL trial consistent with improved major molecular response (MMR) rate of Scemblix (asciminib) vs. Bosulif* (bosutinib) and lower discontinuation rate due to adverse

Updated 48-week data from Phase III ASCEMBL trial consistent with improved major molecular response (MMR) rate of Scemblix® (asciminib) vs. Bosulif®*...

/PRNewswire/ -- Novartis today announced new 48-week data from the Phase III ASCEMBL trial of Scemblix® (asciminib) demonstrating that the results observed in...

BASEL (dpa-AFX) - Swiss drug major Novartis (NVS) announced Monday that the US Food and Drug Administration approved Scemblix (asciminib) for the treatment of chronic myeloid leukemia or CML in

  Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate...

Investegate announcements from NOVARTIS AG CHF0.50(REGD), FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia

Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate response after at least two previous tyrosine